KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Repayments (2020 - 2021)

Historic Long-Term Debt Repayments for AbCellera Biologics (ABCL) over the last 2 years, with Q2 2021 value amounting to $107000.0.

  • AbCellera Biologics' Long-Term Debt Repayments rose 27258.06% to $107000.0 in Q2 2021 from the same period last year, while for Dec 2021 it was $1.8 million, marking a year-over-year decrease of 9085.85%. This contributed to the annual value of $1.8 million for FY2021, which is 9085.85% down from last year.
  • Latest data reveals that AbCellera Biologics reported Long-Term Debt Repayments of $107000.0 as of Q2 2021, which was up 27258.06% from $1.7 million recorded in Q1 2021.
  • AbCellera Biologics' Long-Term Debt Repayments' 5-year high stood at $15.0 million during Q3 2020, with a 5-year trough of -$62000.0 in Q2 2020.